ALNY Alnylam Pharmaceuticals

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Achieved first profitability in 2025 with net product revenues approx. $3.0B, primarily from TTR franchise growth
• • Initiated Phase 3 trials in 2025 for nucresiran (next-gen TTR silencer) and zilebesiran (hypertension), emphasizing late-stage pipeline expansion

Risk Factors

• • Regulatory risk from U.S. drug price control measures, Medicare/Medicaid reimbursement changes potentially reducing AMVUTTRA net price
• • Geopolitical exposure to foreign currency fluctuations in Japanese yen, Euro, and British pound affecting revenues and expenses

Risk Factors

• • New risk: AMVUTTRA U.S. launch March 2025 for ATTR amyloidosis with cardiomyopathy increases commercialization risk
• • Updated financial risk: Accumulated deficit $7.16B as of Sept 30, 2025; product revenues $851.1M Q3, $1.99B YTD with ongoing operating losses

Management Discussion & Analysis

• • No quarterly revenue or YoY figures disclosed in this MD&A excerpt
• • No profitability or margin data provided for current quarter or YoY comparison

What are the latest ALNY SEC filings in 2026?

Alnylam Pharmaceuticals (ALNY) has filed a 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 30, 2025, an 8-K current report on April 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ALNY file its most recent 10-K annual report?

Alnylam Pharmaceuticals (ALNY) filed its most recent 10-K annual report on February 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ALNY 10-Q quarterly reports?

Alnylam Pharmaceuticals (ALNY)'s most recent 10-Q quarterly report was filed on October 30, 2025. SignalX displays every ALNY 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ALNY filed recently?

Alnylam Pharmaceuticals (ALNY)'s most recent 8-K was filed on April 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ALNY insider trading activity (Form 4)?

SignalX aggregates every ALNY Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ALNY file with the SEC?

Alnylam Pharmaceuticals (ALNY) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ALNY filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Alnylam Pharmaceuticals (ALNY).

What is ALNY's SEC CIK number?

Alnylam Pharmaceuticals (ALNY)'s SEC CIK (Central Index Key) number is 1178670. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1178670 to look up all ALNY filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ALNY return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Alnylam Pharmaceuticals (ALNY) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.